跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 131 条关于
“BEXMAB”
全部
131
临床试验
55
药物
34
机构
8
资讯
34
去年
Faron Pharmaceuticals Completes Enrollment in BEXMAB Phase II MDS Trial
去年
Faron Pharmaceuticals' Bexmarilimab Shows Promise in Myelodysplastic Syndrome Treatment
去年
Faron Pharma's Bexmarilimab Receives UK Fast-Track Status for Myelodysplastic Syndrome Treatment
上个月
Faron Reports Encouraging First Overall Survival Data for Bexmarilimab in Frontline HR-MDS, Median OS Not Yet Reached in Key Subgroups
去年
Faron Pharmaceuticals Secures €12M to Advance Promising MDS Treatment Bexmarilimab
去年
Faron Pharmaceuticals Appoints Ralph Hughes as Chief Business Officer to Advance Immunotherapy Pipeline
9个月前
Faron Pharmaceuticals Advances Bexmarilimab with New Phase II Trial and Promising ASH Data in Blood Cancers
去年
Faron Pharmaceuticals Reports 43% Complete Remission Rate in High-Risk Myelodysplastic Syndrome Trial
去年
FDA Grants Orphan Drug Designation to Bexmarilimab for Myelodysplastic Syndrome Treatment
去年
Faron Secures Extended Patent Protection for Bexmarilimab Cancer Immunotherapy Through 2040
第 1 页,共 4 页
上一页
下一页